Tempest Therapeutics Gets Nasdaq Delisting Notice Over Equity Rule
Tempest Therapeutics said Nasdaq notified it on Nov. 17, 2026 that it missed the terms of an extension to regain compliance with the $2.5 million minimum stockholders' equity rule, and it plans to appeal.
What happened
Tempest Therapeutics, Inc., a clinical-stage biotechnology company based in Brisbane, California, disclosed in a Form 8-K filed Nov. 20, 2026 that it received a delisting notification from the Nasdaq Listing Qualifications Staff on Nov. 17, 2026.
According to the filing, the notification states that Tempest did not meet the terms of an extension to regain compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders' Equity Rule. The filing says specifically that the company had failed to complete a capital raising transaction needed to regain compliance. The filing does not identify a buyer, terms, or timing for any such transaction.
The company said it plans to appeal the determination by timely requesting an oral hearing before the Nasdaq Hearings Panel under Nasdaq Listing Rule 5815. Tempest's common stock, ticker TPST, closed at $0.287 on the event date, down 6.21% from the prior close of $0.306, according to the price data.
Background on the compliance process
The filing recounts that Tempest received an initial notice from Nasdaq on May 19, 2026, after reporting stockholders' equity below $2.5 million in its Form 10-Q for the quarter ended March 31, 2026. The company submitted a compliance plan, and on Oct. 30, 2026 the Staff extended the deadline to Nov. 16, 2026 to regain compliance.
The Nov. 17 delisting notification followed the expiration of that extension. Nasdaq's rule sets a minimum level of stockholders' equity — the accounting measure of assets minus liabilities — that a company must maintain to keep a listing on the Nasdaq Capital Market.
What this means
A delisting notification is Nasdaq's formal finding that a company has failed a continued-listing standard. It is not itself the removal of the stock from the exchange. Tempest's filing states that its request for a hearing will stay any suspension or delisting action while the appeal is pending, and that the common stock will continue to trade on the Nasdaq Capital Market during that period.
The timeline described in the filing: hearings are typically scheduled 30 to 45 days after the hearing request, and the Hearings Panel typically issues a decision within 30 days after the hearing. The company stated it cannot provide assurances that the appeal will succeed or that the stock will continue to trade on Nasdaq after the hearing.
The specific trigger here is the stockholders' equity standard, not a minimum share price. Tempest reported equity of less than $2.5 million as of March 31, 2026. The company said the extension required it to complete a capital raising transaction, meaning a sale of stock or other securities that would add to equity, and that it did not complete one by the Nov. 16 deadline.
For a clinical-stage drug developer, equity on the balance sheet reflects accumulated spending on research and trials against the capital raised. A capital raise adds equity; operating losses reduce it. The filing does not state why the company did not complete a financing, and this article does not infer a reason.
About the company
Tempest Therapeutics is listed in SEC records under pharmaceutical preparations and is headquartered at 2000 Sierra Point Parkway, Suite 400, Brisbane, California. Its common stock and Series A Junior Participating Preferred Purchase Rights are registered on Nasdaq; the rights are listed under the symbol N/A in the filing's cover table.
Sources
- 8-K filed 2026-11-20
- Daily price history
Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.